

INFORMATII PERSONALE

Nume / Prenume POPOVICIU (fosta ALBU), Mihaela-Simona
Adresa
Telefon
Email
Nationalitate
Data nasterii
Sex

LOCUL DE MUNCA VIZAT / DOMENIUL OCUPATIONAL

Locul de munca vizat Profesor Universitar – Pozitia 5, Disciplina Semiologie Medicala / Discipline
Medicale, Universitatea din Oradea, Facultatea de Medicina si Farmacie
Domeniul ocupational Sanatate – Invatamant Medical Superior – Cercetare Clinica

EXPERIENȚA PROFESIONALĂ

2023 – prezent **Medic coordonator – Programul National de Diabet Zaharat si Hemoglobina
Glicata**
Spitalul Clinic Judetean de Urgenta Bihor, Oradea (Decizia nr. 2959/31.08.2022)

2023 – prezent **Medic-Sef Sectie Medicina Interna I (N) / Diabet, Nutritie si Boli Metabolice**
Spitalul Clinic Judetean de Urgenta Bihor-Oradea

2022 – prezent **Membru – Comisia Nationala de Diabet, Nutritie si Boli Metabolice, Ministerul
Sanatatii**
(OMS nr. 75/08.03.2022)

2022 – prezent **Medic Primar Diabet, Nutritie si Boli Metabolice**
Spitalul Clinic Judetean de Urgenta Oradea (OMS Nr 1200/iunie 2009)

2009 – prezent **Medic Primar Medicina Interna**
Spitalul Clinic Judetean de Urgenta Oradea (OMS nr 1067 din 25 /08/2004)

2003 – 2004 **Medic Specialist Diabet, Nutritie si Boli Metabolice**
Spitalul Clinic Judetean de Urgenta Oradea (OMS 1190/ octombrie 2003)

1999 – 2003 **Medic Specialist Medicina Interna**
Spitalul Clinic Judetean de Urgenta Oradea (OMS 900/1999)

1995 – 1999 **Medic Rezident Medicina Interna**
Spitalul Clinic Judetean de Urgenta Oradea (OMS 12)

1993 – 1994 **Medic de Adulti**
Dispensarul Medical Suplacu de Barcau, Bihor

1991 – 1993 **Medic Stagiar – Medicina Generala**

Activitate universitara

- 2006 – prezent **Conferentiar Universitar – Disciplina Semiologie Medicala / Discipline Medicale-OMEN/4900/11/11/2002**
Decizia Nr 1861/p/10/09/2006 titular pozitia Nr 23 Catedra Medicina-Limba Engleza Disciplina Semiologie Medicala
- Titular: Semiologie Medicala – MG An III, S1+S2 – romana si engleza
 - Coordonator de Rezidentiat jud. Bihor – Diabet, Nutritie si Boli Metabolice (acreditat MS)
 - Coordonator rezidentiat a 2-a specialitate (acreditat MS)
 - Mentor doctorat – 4 doctoranzi in curs; coordonator lucrari de licenta
 - Activitate didactica cu rezidentii; membru comisii de examen si concurs
- 2004 – 2006 **Sef de Lucrari – Disciplina Semiologie Medicala / Discipline Medicale**
Universitatea din Oradea, Facultatea de Medicina si Farmacie Decizia nr 1101/p/01/10/2004 titular prin concurs pozitia 6 discipline:Semiologie Medicala catedra Medicala V
- Curs + stagii Semiologie Medicala – MG An III, S1+S2, romana si engleza
- 1996 – 2004 **Asistent Universitar – Disciplina Semiologie Medicala / Discipline Medicale**
Universitatea din Oradea, Facultatea de Medicina si Farmacie Decizia nr 10920/16/10/1996 titular prin concurs pozitia 20 discipline Semiologie Medicala la Catedra de Medicina Interna
- Activitate didactica cu studentii An III Medicina Generala – lucrari practice
- 1994 – 1996 **Preparator Universitar – Disciplina Semiologie Medicala / Discipline Medicale**
Universitatea din Oradea, Facultatea de Medicina si Farmacie Decizie nr 341 din 01.10.1994 titular prin concurs Catedra de Medicina Interna pozitia 16 discipline : Semiologie Medicala

EDUCATIE SI FORMARE

- 2024 **Atestat de Abilitare in domniul de studii universitare de Doctorat – Medicina**
Decizia CNATDCU OME nr 4229/10/04/2024
- Teza de abilitare: Contributii fiziopatologice si clinice in bolile metabolice si medicina interna.
- 2024 **Masterat – Managementul Serviciilor de Sanatate (sesiunea iulie 2024, forma cu frecventa)**
Universitatea din Oradea Seria MA Nr 0474456/
- 2010 **Masterat in Formarea Profesorilor**
Universitatea din Oradea – Departamentul pentru Pregatire si Perfectionare a Personalului Didactic (Seria E nr. 0024429)
- 2010 **Certificat de competenta pentru cercetare clinica – GCP**
Vienna School of Clinical Research – conform normelor Europene actualizate
- 2006 **Manager de Proiect**
Ministerul Muncii, Familiei, Egalitatii de Sanse – Certificat Seria F / nr. 0173674 din 15.12.2006
- 2002 **Doctor in Stiinte Medicale – OMEN 4900/11.11.2002**
Universitatea din Oradea
- Titlul tezei: "Studiul comparativ al incidentei si gravitatii leziunilor gastrice provocate de administrarea unor antiinflamatoare nesteroidiene"
 - Conducator stiintific: Prof. Dr. Doc. Barbu Cuparencu
- 1985 – 1991 **Licenta in Medicina Generala**
Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj-Napoca

1984 **Absolvent de Liceu – Sectia Matematica-Fizica**
Liceul Emanoil Gojdu, Oradea

Cursuri postuniversitare relevante (selectie)

- 2026-Cum sa-ti pui pacientul pe pompa de insulina (ed.25) Oradea 19-21 iunie)**
2023-Boala renala cronica si boala hepatica steatotica asociata disfunctiei metabolice in diabetul zaharat -Cursul Societatii Romane De Diabet Nutritie si Boli Metabolice -07/Dec .
- 2022 **Cum sa-ti pui pacientul pe pompa de Insulina (ed. 24)Oradea ,24-26 iunie 2022)**
- 2019 **Rebalancing interconnected systems in T2D: Guidelines-supported treatment approaches**
Across T2D Academy, Viena, Austria, 28-29 noiembrie 2019
- 2010 **EP 2010 on Master Classes in Preventive Cardiology 1: Management of Diabetes in CVD patients**
ESC Educational Programme, European Heart House, Franta, 17-19 iunie 2010
- 2008 **First Diabetes & Cardiovascular Disease – postgraduate course**
Sibiu, Romania, 3-5 noiembrie 2008 / EASD Study Group
- 2004 **Actualitati in managementul serviciilor de sanatate**
Ministerul Sanatatii – Centrul National de Perfectionare Postuniversitara, Bucuresti
- 2003 **Type 2 Diabetes and Its Chronic Complications – 2nd Nicolae Paulescu Advanced EASD Postgraduate Course**
Cluj-Napoca, 11-12 noiembrie 2003
- 2000 / 2001 / 2002 **Cours de Formation Post-Universitaire dans le Domaine des Sciences de la Vie (3 editii)**
L'Universite Franchophone CEFOR – Universitatea din Oradea & Universite Paris-Sud

COMPETENTE PERSONALE

Limba materna Romana

Alte limbi straine cunoscute Niveluri: A1/A2 Utilizator elementar • B1/B2 Utilizator independent • C1/C2 Utilizator experimentat (Cadru European Comun de Referinta pentru Limbi)

	INTELEGERE		VORBIRE		SCRIERE
	Ascultare	Citire	Participare la conversatie	Discurs oral	Exprimar
Engleza	C2	C2	C2	C1	C2
Franceza	B2	B2	B1	B1	B2

Competente organizationale / manageriale

Competente organizatorice, administrative si profesionale dobandite in activitatea de:

- Coordonator de Rezidentiat pe jud. Bihor – Diabet, Nutritie si Boli Metabolice (acreditat MS)
- Coordonator acreditat MS pentru a 2-a specialitate
- Mentor doctorat – 4 doctoranzi in curs (2024-2026)
- Coordonator lucrari de licenta – sectia romani si sectia englezi
- Membru organizator / Chairman in comitete stiintifice si la numeroase manifestari stiintifice
- Membru in Comitetul de organizare al Congreselor Nationale SRDNBM Oradea 2000 si 2006
- Expert evaluator CNCISIS, ARACIS (2005-2006)
- Competente de comunicare dobandite prin masteratul in pedagogie (2010)

Competente digitale

MS Office (Word, Excel, PowerPoint); platforme e-learning; instrumente AI pentru educatie medicala si cercetare; software statistic medical

ACTIVITATE STIINTIFICA SI PUBLICISTICA

- Teze
- T1. Teza de doctorat: "Studiul comparativ al incidentei si gravitatii leziunilor gastrice provocate de administrarea unor antiinflamatoare nesteroidiene". Universitatea din Oradea, 2002. Conducator stiintific: Prof. Dr. Doc. Barbu Cuparencu.
 - T2. Teza de abilitare: Contributii fiziopatologice si clinice in bolile metabolice si medicina interna. 2024.

- Carti publicate (7)
- A1. Popoviciu M. Semiologia aparatului renal. Ed. Universitatii din Oradea, 2005, 135 pg., ISBN 973-613-841-0.
 - A2. Popoviciu M. Indrumar de semiologie al aparatului renal. Ed. Universitatii din Oradea, 2005, 107 pg., ISBN 973-613-840-2.
 - A3. Popoviciu M. Antiinflamatoarele nesteroidiene – efecte asupra mucoasei gastrice. Ed. Universitatii din Oradea, 2005, 87 pg., ISBN 973-613-839-9.
 - A4. Popoviciu M.S. Diabetes Mellitus Integrated Course with Clinical Applications. Ed. Universitatea din Oradea, 2025, 112 pg., ISBN 978-606-10-2437-7.
 - A5. Popoviciu M.S. Managementul cazurilor clinice de medicina interna. Diabet. Integrarea data learning-ului, dialogului interdisciplinar si aplicarea ghidurilor. **Oradea 2025**, 210 pg., ISBN 978-606-10-2421-6.
 - A6. Popoviciu M.S.:Diabet si Boli de nutritie .Editura Universitatii din Oradea ,**2026**.
 - A7. Popoviciu M.S. Introducere in diabet si nutritie clinica. Ed. Universitatii din Oradea, **2026**. ISBN 978-606-10-2491-9.

- Capitole in volume colective (9)
- B1. Popoviciu M. Capitol Renale, pg. 210-250. In: Babes K. (coord.): Sindroame medicale. Ed. Universitatii din Oradea, 2009, ISBN 978-973-759-873-8.
 - B2. Popoviciu M. Capitol Abcesul Pulmonar, pg. 173-190. In: Demian L.D. (coord.): Aparatul Respirator – curs medicina interna. Ed. Universitatii din Oradea, 2008, ISBN 978-973-759-695-6.
 - B3. Popoviciu M. Capitol Hipertensiunea Arteriala, pg. 347-415. In: Demian L.D. (coord.): Aparatul Cardio-vascular – curs medicina interna. Ed. Universitatii din Oradea, 2008.
 - B4. Demian L.D., Popoviciu M. Manifestari tegumentare in DZ, pp. 467-483. In: Popa A.R. (coord.): Complicatiile cronice ale DZ. Ed. Farma Media Tg. Mures, 2008, ISBN 978-973-87462-8-2.
 - B5. Popa A.R., Popescu M., Rosca A., Furau G., Popoviciu M., et al. Internal Diseases: Diabetes mellitus. Metabolic diseases. Nutrition. Ed. Universitatii din Oradea, 2004, 254 pg., ISBN 973-613-566-7.
 - B6. Popoviciu M.: Cap. XXII, XXIII, XXIV, pg. 135-174. In: Babes P.A. (coord.): Semiologie medicala, vol. II. Ed. Imprimeria de Vest Oradea, 2001, ISBN 973-8195-35-7.
 - B7. Popoviciu M.S. Cap. 5: Hemochromatosis, pp. 289-297. In: Bruckner I.I. (ed.). Tratat de Medicina Interna, Vol. 3. Ed. Medicala, Bucuresti, 2024. ISBN 978-973-39-0949-1.
 - B8. Popoviciu M.S. Inovatie terapeutica si perspective multidisciplinare in managementul DZ si risc CV, pp. 19-23. In: Pantea Stoian A. (coord. st.). Viata Medicala. MedicHub Media, Bucuresti, 2025. ISBN 978-630-6631-17-9.
 - B9. Popoviciu M.S. Sectiunea 24: Diabetul la varstnic (Cap. 24.1-24.3), pp. 693-706. In: Timar B. (coord.). Tratat de Diabet, Nutritie si Boli Metabolice. Ed. Victor Babes, Timisoara, 2026. ISBN 978-606-786-533-2.

- Articole ISI/Scopus autor principal (21)
- 1. Popoviciu M.S., Pop A.M., Ghitea T.C., Dorobantu F.R., Pantis C., Pop N.O., Brata R.D. HbA1c as a Continuous Marker of Microvascular Vulnerability: Development of a Non-Linear Risk Framework in a Real-World Cohort. *Metabolites* 2026, 16(3), 197. doi:10.3390/metabo16030197
 - 2. Popoviciu M.S., Ghitea T.C., Pantis C., Brata R.D. Determinants of HbA1c Variability Across Clinical Subgroups: When the Same Value Does Not Reflect the Same Biological Risk. *Medicina* 2026, 62(3), 451. doi:10.3390/medicina62030451
 - 3. Popoviciu M.S., Ghitea T.C., Pantis C., Pop N.O., Brata R.D. HbA1c-Based Metabolic Stratification: A Retrospective Study of Clinical and Biological Differences Across Normoglycemic, Prediabetic, and Diabetic Subjects. *Diagnostics* 2026, 16(4), 566. doi:10.3390/diagnostics16040566
 - 4. Popoviciu M.S., Ghitea T.C. Age-Stratified Differences in Cardio-Reno-Metabolic Risk Profiles. *Geriatrics* 2026, 11(1), 18. doi:10.3390/geriatrics11010018

5. Popoviciu M.S., Moldovan A., Dorobantu F.R., et al., Ghitea T.C., Manole F. Integrative Assessment of TyG Index, FIB-4, and eGFR as Composite Predictors of Metabolic Risk Clusters. *Metabolites* 2025, 15, 729. doi:10.3390/metabo15110729
6. Popoviciu M.S., Reurean-Pintilei D., Salmen T., Rus M., Ferician A., Sava C., Ardelean A.I., Moroianu L.-A., Pantea Stoian A. Translating Guidelines into Practice: A Prospective Real-World Study of a Romanian Cohort Treated with GLP-1 RAs. *Biomedicines* 2025, 13, 2174. doi:10.3390/biomedicines13092174
7. Cosma-Lazuran R., Leucuta D.-C., Popoviciu M.-S. Systemic Immune-Inflammation Index and Related Hematologic Markers as Prognostic Tools in Type 2 Diabetes. *Medicina* 2025, 61, 1433. doi:10.3390/medicina61081433
8. Popoviciu M.-S., Salmen T., Reurean-Pintilei D., Voiculescu V., Pantea Stoian A. SGLT-2i—A Useful Tool for Real-Life Metabolic and Body Weight Control in Type 2 Diabetes Mellitus Patients. *Medicina* 2025, 61, 548. doi:10.3390/medicina61030548
9. Paduraru L., Zaha D.C., Ghitea T.C., Fodor R., Vesa C.M., Popoviciu M.S. Integrating Renal and Metabolic Parameters into a Derived Risk Score for Hyperuricemia in Uncontrolled Type 2 Diabetes. *Medicina* 2025, 61, 2042. doi:10.3390/medicina61112042
10. Popoviciu M.S., Paduraru L., Rahman M.M., Supti F.A., Stoica R.A., Reurean-Pintilei D., Bica C.I., Cavalu S. The Effects of SGLT2 Inhibitors in Patients with MAFLD; A Narrative Review. *J. Mind Med. Sci.* 2024, 11, 62-77. doi:10.22543/2392-7674.1439
11. Popoviciu M.S., Paduraru L., Nutas R.M., Ujoc A.M., Yahya G., Metwally K., Cavalu S. Diabetes Mellitus Secondary to Endocrine Diseases: An Update of Diagnostic and Treatment Particularities. *Int. J. Mol. Sci.* 2023, 24, 12676. doi:10.3390/ijms241612676
12. Popoviciu M.-S., Paduraru L., Yahya G., Metwally K., Cavalu S. Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials. *Int. J. Mol. Sci.* 2023, 24, 10449. doi:10.3390/ijms241310449
13. Youssef M.E., Yahya G., Popoviciu M.S., Cavalu S., Abd-Eldayem M.A., Saber S. Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control. *Int. J. Mol. Sci.* 2023, 24, 6039. doi:10.3390/ijms24076039
14. Ali I., Rasheed M.A., Cavalu S., Rahim K., Ijaz S., Yahya G., Goh L.P.W., Popoviciu M.S. Identification of Natural Lead Compounds against Hemagglutinin-Esterase Surface Glycoprotein in Human Coronaviruses. *Biomedicines* 2023, 11, 793. doi:10.3390/biomedicines11030793
15. Popoviciu M.S., Kaka N., Sethi Y., Patel N., Chopra H., Cavalu S. Type 1 Diabetes Mellitus and Autoimmune Diseases: A Critical Review. *J. Pers. Med.* 2023, 13, 422. doi:10.3390/jpm13030422
16. Patel N., Sethi Y., Kaka N., et al., Popoviciu M.S., Emran T.B. Acute Hepatitis of Unknown Origin in Pediatric Age Group. *J. Clin. Med.* 2023, 12, 9. doi:10.3390/jcm12010009
17. Popoviciu M.-S., Paduraru L., Stoica R.A., Pantea Stoian A., Teodorescu C., Cavalu S. Prevalence of Comorbidities and Survival Analysis of COVID-19 Patients. *J. Mind Med. Sci.* 2023, 10, 330-338. doi:10.22543/2392-7674.1401
18. Sethi Y., Murli H., et al., Popoviciu M.S., Cavalu S. Broken Heart Syndrome: Evolving Molecular Mechanisms and Principles of Management. *J. Clin. Med.* 2023, 12, 125. doi:10.3390/jcm12010125
19. Popoviciu M.S., Marin V.N., Vesa C.M., Stefan S.D., Stoica R.A., Serafinceanu C., Merlo E.M., Rizvi A.A., Rizzo M., Busnatu S., et al. Correlations between Diabetes Mellitus Self-Care Activities and Glycaemic Control. *Healthcare* 2022, 10, 174. doi:10.3390/healthcare10010174
20. Popoviciu M.S., Vesa C., Jurca A., Jurca C., Popa L., Zaha D., Ceavoi G., Jurca A. Real-World Observational Study Regarding Glucose Control In Insulin-Treated DM Patients. Glucose Variability Patterns Analysis Using CGMS. *Farmacia* 2021, 69(2), 332-340.
21. Popoviciu M.S., Popa A.R., Demian L. The Metabolic Control In Type 2 Diabetes patients treated with GLARGINE. Abstract Book 5th World Congress WCPD 2008, Helsinki, p.19-07.

Articole ISI/Scopus co-autor
(14)

1. Mosteanu I.M., Parlitanu O.A., Mahler B., et al., Popoviciu M.S., et al. Diabetes Mellitus and COVID-19 in Adults: A Systematic Review. *Int. J. Mol. Sci.* 2026, 27(8), 3537. doi:10.3390/ijms27083537
2. Pantis C., Popoviciu M.S., Ghitea T.C., Pop A.M., Brata R.D. ICU Length of Stay Patterns and In-Hospital Mortality. *Healthcare* 2026, 14(8), 1092. doi:10.3390/healthcare14081092
3. Ghitea T.C., Popoviciu M.S., Moldovan A., et al. Anthropometric and Metabolic Determinants of Multi-Organ Stress in Adults with Obesity: CaRaMeL-O Score. *Healthcare* 2025, 13, 3123. doi:10.3390/healthcare13233123
4. Paduraru L., Vesa C.M., Popoviciu M.S., Ghitea T.C., Zaha D.C. Interrelationship Between Dyslipidemia and Hyperuricemia in Patients with Uncontrolled Type 2 Diabetes.

- Healthcare 2025, 13, 2605. doi:10.3390/healthcare13202605
5. Salmen T., Pietrosel V.-A., Urzica F.-V., et al., Popoviciu M.-S., Pantea Stoian A. Evaluating Cardio-Protective Molecules by Efficacy Based on Weight Reduction and HbA1c Targets. *Biomedicines* 2025, 13, 2306. doi:10.3390/biomedicines13092306
 6. Rus M., Negrutiu B.M., Andronie-Cioara F.L., et al., Popoviciu M.-S., Stanis C.E. Proximal vs. Distal LAD Lesions in STEMI: Insights from ECG and Coronary Angiography. *J. Clin. Med.* 2025, 14, 5637. doi:10.3390/jcm14165637
 7. Mititelu A., Grama A., Colceriu M.-C., Benta G., Popoviciu M.-S., Pop T.L. Role of Interleukin 6 in Acute Pancreatitis. *Int. J. Mol. Sci.* 2024, 25, 8283. doi:10.3390/ijms25158283
 8. Stoica R.A., Gherghiceanu F., Nedelcu D., et al., Popoviciu M.S., Pantea Stoian A. Weight Loss in Subjects with Type 2 Diabetes Before and After SARS-CoV-2 Infection. *J. Mind Med. Sci.* 2024, 11, 505-510.
 9. Tirla A., Timar A.V., Becze A., et al., Popoviciu M.S., Cavalu S. Designing New Sport Supplements Based on Aronia melanocarpa and Bee Pollen. *Molecules* 2023, 28, 6944. doi:10.3390/molecules28196944
 10. Galusca D., Popoviciu M.S., Babes E.E., et al. Vitamin D Implications and Effect of Supplementation in Endocrine Disorders. *Medicina* 2022, 58, 194. doi:10.3390/medicina58020194
 11. Baidog A., Vesa C., Daina L., et al., Popoviciu M., Galusca D. Parathormone and vitamin levels in CKD and DM. *Ageing Clin. Exp. Res.* 2022, 34, S123.
 12. Bondar A., Popa A.R., Papanas N., Popoviciu M., et al. Diabetic Neuropathy: A narrative review. *Exp. Ther. Med.* 22(2021):690. doi:10.3892/etm.2021.10122
 13. Hegedus C., Muresan M., Badale A., et al., Popoviciu M., et al. SIRT1 Activation by Equisetum Arvense L. Modulates Insulin Sensitivity in Diabetic Rats. *Molecules* 2020, 25(11), 2541. doi:10.3390/molecules25112541
 14. Paduraru L., Jurca A.D., Zaha D.C., Dorobantu F.R., Hasan M.A., Popoviciu M.S. Aetiology of Bacterial Infections and Antibiotic Resistance in Pediatric Patients. *Pharmacophore* 2022, 13(6), 77-83.

Experienta in studii clinice (29,
2003–2026)

IP = Investigator Principal

- A1. Sibutramine CV Morbidity/Mortality Study (Mo1-392), MDS Pharma Services Romania, 07.02.2003–07.03.2009. Rol: Sub-investigator.
- A2. LAF237 (Vildagliptin) 50 mg bid vs Acarboza 100 tid – DZ tip 2 netratati anterior (faza III, multicentric, dublu orb), IFE Romania, 04-05.2005. Rol: Sub-investigator.
- A3. LAF237 (Vildagliptin) 50 mg bid vs placebo ca terapie suplimentara la Tiazolidindion (faza III, multicentric, dublu orb), IFE Romania, 18.10.2004–26.01.2006. Rol: Sub-investigator.
- A4. LAF237 (Vildagliptin) 50 mg + Pioglitazona 45 mg – extensie 28 sapt. (faza III, multicentric, dublu orb), IFE Romania, 30.05.2005–26.01.2007. Rol: Sub-investigator.
- A5. LAF237 (Vildagliptin) 50 mg bid vs Glicazide 320 mg/zi in DZ tip 2 drug-naive (faza III, multicentric, dublu orb), Clinical Trial Centre Romania, 10.11.2005–10.11.2006. Rol: Sub-investigator.
- A6. Insulina Glulizina + Insulina Glargina – regim intensificat vs conventional in DZ tip 2 (faza IV, deschis, multicentric, Study nr. HMR 1964/3504, Aventis Sanofi Romania), 07.05.2006. Rol: Co-investigator.
- A7. FENOPRA-III-06-1 – Fenofibrat 160 mg/Pravastatina 40 mg +/- Ezetimib 10 mg vs Simvastatina 20 mg in DZ tip 2 cu hiperlipemie mixta (faza III, dublu orb). 05.03.2008–05.11.2008. Rol: Investigator Principal.
- A8. CLAF237A23135 – Vildagliptin 50 mg bid add-on la insulina +/- metformina in DZ tip 2 (24 sapt., multicentric, dublu orb, placebo-controlled). 04.04.2011–13.10.2011. Rol: Investigator Principal.
- A9. CLAF237A23152 – Vildagliptin 50 mg bid add-on la metformina + glimepirid in DZ tip 2 (24 sapt., multicentric, dublu orb, placebo-controlled). 31.01.2011–24.08.2011. Rol: Investigator Principal.
- A10. CLAF237B2224 – Vildagliptin MR add-on la metformina – eficacitate si siguranta pe termen lung in DZ tip 2 (multicentric, randomizat, dublu orb). 06.04.2009–28.03.2011. Rol: Investigator Principal.
- A11. 411-MA-08-01-0000 – Imunogenicitate comparativa a doua branduri de insulina umana in DZ (randomizat, dublu orb). 29.10.2009–17.08.2011. Rol: Investigator Principal.
- A12. CLCZ696A2223 – AHU377 + Valsartan 320 mg – evaluare raspuns doza vs placebo si activ in HTA sistolica usoara/moderata (multicentric, dublu orb, 8 sapt.). 08.08.2011–07.12.2011. Rol: Investigator Principal.
- A13. H9X-MC-GBDB AWARD-2 – LY2189265 (Dulaglutida) vs Insulina Glargina pe fond de Metformina + Glimepirid in DZ tip 2 (randomizat, open-label, non-inferioritate). 04.06.2010–01.03.2013. Rol: Investigator Principal.

- A14. I4-MC-ABEB Element 1 – LY2963016 (Biosimilar Insulina Glargina) vs Lantus + Insulina Lispro in DZ tip 1 (randomizat, open-label, prospectiv). 18.01.2012–12.06.2013. Rol: Investigator Principal.
- A15. CLAF237A23156 – Vildagliptin + Metformina vs Metformina monoterapie – durabilitate control glicemic pe 5 ani in DZ tip 2 (multicentric, randomizat, dublu orb). 30.05.2012–26.06.2019. Rol: Investigator Principal.
- A16. LANCELOT-LANTU_C_02762 – Insulina Glargina Lantus vs NPH – treat-to-normoglycemia in DZ tip 2 naiv la insulina (randomizat). 22.07.2011–14.11.2012. Rol: Investigator Principal.
- A17. FENOPRA-III-12-1 – Fenofibrat 160 mg/Pravastatina 40 mg (Pravafesix) vs Atorvastatina 20 mg in dislipemie mixta cu risc CHD inalt (faza III, dublu orb, 12 sapt.). 13.06.2014–22.12.2014. Rol: Investigator Principal.
- A18. MK8835 – Ertugliflozin (MK-8835/PF-04971729) in DZ tip 2 cu BCR stadiu 3 (faza III, multicentric, randomizat, dublu orb, placebo-controlled). 05.03.2015–07.10.2015. Rol: Investigator Principal.
- A19. SPIRE B1481038 – Bococizumab (PF-04950615) vs placebo – reducere MACE in subiecti cu risc CV inalt (faza 3, multicentric, dublu orb, placebo-controlled). 30.06.2015–11.05.2017. Rol: Investigator Principal.
- A20. SPIRE B1481022 – Bococizumab (PF-04950615) vs placebo – reducere MACE in subiecti cu risc CV inalt (faza 3, multicentric, dublu orb, placebo-controlled). 30.06.2015–11.05.2017. Rol: Investigator Principal.
- A21. RECAP MK-0431 – Eficienta reala a tratamentului cu sulfoniluree in DZ tip 2 in Romania (studiu observational, prospectiv). 08.11.2017–26.02.2018. Rol: Investigator Principal.
- A22. CLEAR OUTCOMES – Bempedoic Acid (ETC-1002) vs placebo – reducere MACE la pacienti intolerant la statine cu risc CV inalt (randomizat, dublu orb). 06.11.2018–17.01.2023. Rol: Investigator Principal.
- A23. I8B-MC-ITRM PRONTO-T1D – LY900014 (Insulina Lispro ultra-rapida) vs Insulina Lispro + Insulina Glargina/Degludec in DZ tip 1 (randomizat, dublu orb, prospectiv). 03.07.2017–05.09.2019. Rol: Investigator Principal.
- A24. OPO-ALD-CHF-301 – Alendronat + Vitamina D3 vs comparator activ in osteoporoza la femei (faza III, multicentric, randomizat, dublu orb, 15 sapt.). 03.2012–04.2012. Rol: Investigator Principal.
- A25. SUSTAIN – Semaglutida s.c. 2.0 mg o data/sapt. + Insulina Glargina doza redusa vs Insulina Glargina titrata in DZ tip 2 cu suprapondere (randomizat, dublu orb). 06.10.2022–04.06.2025. Rol: Investigator Principal.
- A26. SERVIER CL3-005179-002 – Perindopril 10 mg/Indapamid 2.5 mg/Amlodipina 5 sau 10 mg/Bisoprolol 5 mg (SPC) vs combinatie libera in HTA esentiala necontrolata (multinational, multicentric, randomizat, dublu orb, 16 sapt.). 06.02.2023–11.10.2023. Rol: Investigator Principal.
- A27. VICTORION-1 PREVENT – Inclisiran vs placebo – prevenire MACE la pacienti cu risc CV inalt in preventie primara (randomizat, dublu orb, multicentric). 26.02.2024 – IN DERULARE. Rol: Investigator Principal.
- A28. J20-MC-EKBG MOVE-LP(a) – Muvalaplin vs placebo – reducere MACE la pacienti cu Lp(a) crescut si ASCVD confirmat sau risc pentru un prim eveniment ASCVD (faza 3, randomizat, dublu orb). 10.10.2025 – IN DERULARE. Rol: Investigator Principal.
- A29. AMAZE 8 – NNCO487-0111 s.c. o data/sapt. vs Semaglutida s.c. o data/sapt. in suprapondere sau obezitate cu DZ tip 2 (faza 3). Din iunie 2026 – IN DERULARE. Rol: Investigator Principal.
- C1. Diovan (Valsartan) – monitorizare clinica la pacienti hipertensivi, Novartis Pharma Services Inc., 2002-2003. Rol: Co-investigator.
- C2. NovoMix 30 – post-marketing surveillance in DZ tip 2 (long-term safety/efficacy, open-label, prospectiv), Novo Nordisk Company, 2003. Rol: Co-investigator.
- C3. NovoRapid (Insulina Aspart) – monitorizare clinica in DZ tip 2, Novo Nordisk Company, 2002-2003. Rol: Co-investigator.
- C4. Novonorm (Repaglinida) – monitorizare clinica in DZ tip 2, Novo Nordisk Company, 2002-2003. Rol: Co-investigator.
- C5. Assessment of performance of commonly used insulin delivery systems in T2DM (outpatient, observational multicentric), Eli Lilly Romania, 02.02.2005–28.02.2006. Rol: Sub-investigator.
- C6. Amaryl (Glimepirid) – evaluare eficacitate si siguranta in DZ tip 2 nou diagnosticat sau necontrolat (BMI 25-35 kg/m², observational), Aventis Romania, 10.08.2004–10.08.2005. Rol: Co-investigator.
- C7. Impactul intensificarii insulinoterapiei cu Insulina Glargina + Insulina Glulizina conform recomandarilor ADA/EASD in practica curenta (studiu observational non-randomizat, retrospectiv, multicentric non-interventional), mai–decembrie 2011.

Proiecte de cercetare	B1. Grant CEEX 2005-2008 – CARDIAB: "Corelatia dintre disfunctia endoteliala si afectarea miocardica la pacientii cu diabet zaharat". Valoare: 120.000 RON. Rol: Specialist.
Conducere de doctorat (4 doctoranzi in curs)	1. Cipleu (Popovici) Paula-Alexandra – Adherence to treatment in patients with type 2 diabetes mellitus. 2. Criste Bianca-Lacrimioara – Stratificarea riscului cardiovascular in functie de Apolipoproteina B la pacientii cu DZ tip 2. 3. Igna Andreea-Diana – Multiparametric control in patients with type 2 diabetes depending on therapeutic classes 4. Lazuran (Cosma-Lazuran) Raluca – Prognosticul riscului de deces cardiovascular in functie de raportul neutrofile/limfocite la pacientii cu DZ tip 2.

INFORMATII SUPLIMENTARE

Distinctii si premii	• Premiul Societatii Romane de Diabet, Nutritie si Boli Metabolice – 2023 • Premiul Societatii Romane de Diabet, Nutritie si Boli Metabolice – 2025
Asociatii profesionale	• Membru in Comitetul Director al SRDNBM – din 2025 • Colegiul Medicilor din Romania – din 1999 • Societatea Romana de Diabet, Nutritie si Boli Metabolice (SRDNBM) – din 2000 • Asociatia Romana pentru studiul Obezitatii (ARSO) – din 2001 • Societatea Romana de Medicina Interna – din 2003 • Federatia Romana de Diabet, Nutritie si Boli Metabolice – din 2005 • Federatia Europeana de Medicina Interna (EFIM) – din 2011 • European Association for the Study of Diabetes (EASD, Germania) – din 2001 • American Diabetes Association (ADA) – din 2004 • Uniunea Medicala Balcanica – din 2002

ATASAMENTE

Lista atasamentelor	• Lista de lucrari completa (LL_2026) • Copii diplome (doctorat, abilitare, masterate, GCP) • Fisa de verificare a eligibilitatii (Anexa 1) • Declaratii Anexa 4 si Anexa 5
---------------------	---

Declar pe propria raspundere ca informatiile din prezentul curriculum vitae sunt corecte si complete.

Data: 28 iunie 2026 Semnatura: _____